New Chromogenic Culture Media Enable Rapid Detection of Candida Infections

Candida auris is associated with serious illness and high mortality, intensifying the need for efficient screening and surveillance. Clinical microbiology laboratories require faster, reliable tools that fit routine workflows. A newly launched set of color-based chromogenic culture media now enables earlier visual differentiation of clinically important Candida species, including direct identification of Candida auris, after shorter incubation than conventional culture methods.

Thermo Fisher Scientific (Waltham, MA, USA) has introduced Thermo Scientific Brilliance Candida 2 Agar and Spectra Candida Agar, color-based chromogenic culture media designed to help laboratories quickly detect and differentiate clinically important Candida species, including Candida auris. The media are positioned to support earlier detection, faster outbreak response, and more informed treatment decisions in healthcare settings. The portfolio is presented as suitable for routine screening as well as outbreak investigations.

The technology produces clear, species-specific chromogenic reactions directly from primary culture. This enables visual differentiation of the most clinically relevant Candida species and direct identification of Candida auris. Incubation times are shorter than with conventional culture methods, supporting timely clinical decisions, appropriate antifungal therapy, and rapid infection control measures. The approach is intended to streamline workflows without adding complexity.

Brilliance Candida 2 Agar is available for purchase in Europe, while Spectra Candida Agar is available in the United States; both are tailored to regional laboratory requirements and are described as offering the same level of performancde. Availability in individual countries depends on local regulatory marketing authorization status. Practical incubation and storage conditions are highlighted to support laboratories of all sizes while maintaining quality and consistency. Collectively, the solutions are described as strengthening efforts in antimicrobial resistance (AMR) surveillance, outbreak preparedness, infection prevention, and Candida diagnostics workflows.

“As new pathogens emerge that threaten patients and healthcare settings, it’s increasingly important that healthcare providers have effective screening strategies that don’t add complexity to routine laboratory workflows,” said Chris Armstrong, president of the microbiology business at Thermo Fisher Scientific. “This new media delivers clear visual differentiation and faster results, helping laboratories respond confidently to emerging fungal threats and strengthening frontline defenses against antimicrobial resistance, while maintaining efficiency and consistency,”

Related Links:
Thermo Fisher Scientific